Printer Friendly

Shionogi, Response Biomedical to Conclude Sales Agreement for Rapid BNP Test.

Tokyo, Japan, May 19, 2006 - (JCN) - Shionogi has concluded a sales agreement with Canadian company Response Medical for the sale of SHIONOSPOT BNP, a point-of-care test reagent, and the SHIONOSPOT Reader in Japan.

SHIONOSPOT BNP, which is based on fluorescent immunochromatographic assay, can measure the levels of B-type natriuretic peptide (BNP) in the blood. BNP is a kind of hormone that reflects deterioration in heart functions.

Used in combination with the SHIONOSPOT Reader, the reagent can obtain results in about 16 minutes. Shionogi expects that the launch of SHIONOSPOT will contribute to the diagnosis and management of congestive heart failure at clinical sites.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:May 19, 2006
Words:113
Previous Article:Fujitsu Develops Plant Plastic with Higher Impact-Resistance.
Next Article:Yakult Honsha to Bring to Market New Intestinal Remedy in June.


Related Articles
QUARK SIGNS RESEARCH PACT WITH SHIONOGI.
Shionogi to Sell Shionogi Qualicaps Group to Carlyle Group.
Shionogi Launches New Quinolone Antibacterial "Avelox(R) Tablet 400mg" (Moxifloxacin Hydrochloride).
Shionogi, Purdue Pharma to Collaborate to Develop and Market New Analgesic Drug Compounds.
Shionogi, Galderma to Promote Acne Medicine Adapalene in Japan.
Shionogi Obtains Manufacturing, Marketing Approval for OXINORM Powder 0.5%.
Shionogi Launches Cancer Pain Analgesic OxiNorm Powder 0.5% in Japan.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters